1. Home
  2. PAHC vs IMNM Comparison

PAHC vs IMNM Comparison

Compare PAHC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAHC
  • IMNM
  • Stock Information
  • Founded
  • PAHC 1946
  • IMNM 2006
  • Country
  • PAHC United States
  • IMNM United States
  • Employees
  • PAHC N/A
  • IMNM N/A
  • Industry
  • PAHC Biotechnology: Pharmaceutical Preparations
  • IMNM Medicinal Chemicals and Botanical Products
  • Sector
  • PAHC Health Care
  • IMNM Health Care
  • Exchange
  • PAHC Nasdaq
  • IMNM Nasdaq
  • Market Cap
  • PAHC 871.9M
  • IMNM 806.1M
  • IPO Year
  • PAHC 2014
  • IMNM 2020
  • Fundamental
  • Price
  • PAHC $21.97
  • IMNM $6.26
  • Analyst Decision
  • PAHC Sell
  • IMNM Strong Buy
  • Analyst Count
  • PAHC 4
  • IMNM 5
  • Target Price
  • PAHC $21.00
  • IMNM $26.60
  • AVG Volume (30 Days)
  • PAHC 258.0K
  • IMNM 1.3M
  • Earning Date
  • PAHC 05-07-2025
  • IMNM 03-19-2025
  • Dividend Yield
  • PAHC 2.25%
  • IMNM N/A
  • EPS Growth
  • PAHC 30.53
  • IMNM N/A
  • EPS
  • PAHC 0.48
  • IMNM N/A
  • Revenue
  • PAHC $1,106,080,000.00
  • IMNM $9,041,000.00
  • Revenue This Year
  • PAHC $28.43
  • IMNM N/A
  • Revenue Next Year
  • PAHC $10.10
  • IMNM $476.80
  • P/E Ratio
  • PAHC $44.79
  • IMNM N/A
  • Revenue Growth
  • PAHC 12.63
  • IMNM N/A
  • 52 Week Low
  • PAHC $12.17
  • IMNM $6.20
  • 52 Week High
  • PAHC $26.55
  • IMNM $22.26
  • Technical
  • Relative Strength Index (RSI)
  • PAHC 48.28
  • IMNM 26.66
  • Support Level
  • PAHC $20.80
  • IMNM $6.94
  • Resistance Level
  • PAHC $21.93
  • IMNM $7.68
  • Average True Range (ATR)
  • PAHC 0.77
  • IMNM 0.56
  • MACD
  • PAHC -0.00
  • IMNM -0.17
  • Stochastic Oscillator
  • PAHC 74.43
  • IMNM 2.12

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Share on Social Networks: